Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease

NCT00162942 is registered in ClinicalTrials.gov with Otsuka America Pharmaceutical as lead sponsor.

NCT NCT00162942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00162942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease
Lead sponsor
Otsuka America Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2005
Completion date
December 31, 2007
Enrollment
235 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease